The Valley Desk

Clinical trial reportJournal of managed care & specialty pharmacyPublished

Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Journal of managed care & specialty pharmacy
Published
Subject terms
Humans; Multiple Myeloma; Neoplasm, Residual; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Models, Economic; Aged; Cost-Benefit Analysis; Health Care Costs; Drug Costs; United States
PubMed ID
42726291
PubMed Central ID
PMC13621899
Added to directory
Source checked

Report a correction or request removal